What Changed — The First Revision Since 2022
According to materials published by the Ministry of Food and Drug Safety (MFDS), a revised Guideline on the Recognition of Incremental Modified Drugs (Guideline-0987-03) was registered on October 30, 2026. It is the first revision in roughly four years, and it makes three key changes.
Why Incremental Modified Drug Status Matters
Recognition is tied to a drug price premium. Press reports indicate the premium is expected to remain under the ongoing drug pricing reform, but this should be confirmed against the final notice.
Press reports also say last year saw 20 incremental modified drug approvals, the most in five years, mostly new combinations and strength changes. With generic prices under growing pressure, incremental modified drugs give pharma SMEs a realistic way to reshape their portfolios.
What to Revisit at the Planning Stage
Designing Evidence Beyond PK
Map evidence types to each objective
Decide which evidence fits your objective, such as clinical outcomes, adherence data, or safety (adverse event) data, then check the guideline text for what qualifies.
Fix comparators and endpoints up front
At the nonclinical and clinical design stage, decide what you will compare against the existing product and which endpoints you will use. Data assembled after the fact are much weaker evidence of usefulness.
Use MFDS pre-submission consultation
Request a consultation before locking the design. In your question set, spell out the improvement, comparator, endpoints, and planned data package, and ask questions the agency can actually answer, such as "Would this data package demonstrate usefulness?"
Open Issues for Co-Developed Products
In the aceclofenac–eperisone combination case, only the contract manufacturer received incremental modified drug status and the price premium, while the commissioning company was left out, which caused controversy. Press reports say a separate reform of recognition for co-developed products is under discussion. Until that is settled, the safest course is to clearly define development contributions and data ownership and usage rights in your contract manufacturing agreements.
Action Checklist for Pharma SMEs
KITIM supports you at every step, from incremental modified drug development strategy and evidence design under the revised guideline to government R&D proposals. If you need to check whether a current project can still be recognized, please contact the KITIM consulting team.
